
Exploring MRD Testing and Data in Myeloma to Guide Treatment Decisions
Bispecific antibodies represent a promising advancement in the treatment of relapsed/refractory multiple myeloma, offering targeted immune activation against cancer cells. An in-person Case-Based Roundtable meeting in Dallas, Texas, on bispecific …